On the 16th and 17th of May 2017 the MycoSynVac team met in Brussels at one of the European Commission (EC) buildings for the second Review of the project.
The Project Officer and the Project Monitor were updated on the project progress. During these two years of project, it has been obtained, among other things, the first dynamic models of the M.pneumoniae metabolism, first version of the bacterial chassis as well as promising improvements on bacteria’s growth rate. Also some tools for engineer Mycoplasma genome and some switches and specific circuits have been developed. The team have also identified several membrane proteins useful for the design of the vaccine. In parallel, the consortium has been elaborating a risk assessment study and evaluating what are the ethical concerns related to synthetic biology in the field of vaccines.
The Project Officer and the Monitor provided a very positive feedback on the project progress and encouraged the team to keep working so hard.